AGX-101

N/A

Report date: 2025/06/06 20:01:13

First In Class

Base Information

Drug NameAGX-101

Drug Alias NameAGX101AGX-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Transmembrane 4 L6 family member 1Tubulin modulators

TargetsTransmembrane 4 L6 family member 1Tubulin

Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsPancreatic Neoplasms +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAngiex Inc

China Registration ClassN/A

Develop Information

Active CompaniesAngiex Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursProstatic NeoplasmsPancreatic Neoplasms +[7]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A